A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to
placebo in patients with type 2 diabetes. The anticipated time on study treatment is < 3
months and the target sample size is 100-500 individuals.